Publications by authors named "N de Peyrecave"

Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation is possible using F-fluoride positron emission tomography-computerised tomography (PET-CT) imaging to quantitatively monitor osteoblastic activity.

Objectives: This exploratory study, initiated before phase IIb/III studies, assessed the efficacy and safety of BKZ in patients with radiographic (r-)axSpA and its effect on new bone formation.

View Article and Find Full Text PDF

Objectives: To assess the ability of a previously trained deep-learning algorithm to identify the presence of inflammation on MRI of sacroiliac joints (SIJ) in a large external validation set of patients with axial spondyloarthritis (axSpA).

Methods: Baseline SIJ MRI scans were collected from two prospective randomised controlled trials in patients with non-radiographic (nr-) and radiographic (r-) axSpA (RAPID-axSpA: NCT01087762 and C-OPTIMISE: NCT02505542) and were centrally evaluated by two expert readers (and adjudicator in case of disagreement) for the presence of inflammation by the 2009 Assessment of SpondyloArthritis International Society (ASAS) definition. Scans were processed by the deep-learning algorithm, blinded to clinical information and central expert readings.

View Article and Find Full Text PDF
Article Synopsis
  • This study looked at how well a drug called certolizumab pegol (CZP) works for people with a condition called axial spondyloarthritis (axSpA) over 12 weeks.
  • It found that while most patients showed strong improvements in inflammation measured by tests like blood tests and MRI scans, fewer than half showed similar improvements in their symptoms or daily activities.
  • The results suggest that looking at inflammation alone might not give the full picture of how the treatment is working for patients with axSpA.
View Article and Find Full Text PDF
Article Synopsis
  • Acute anterior uveitis is a common issue in patients with axial spondyloarthritis, and IL-17 plays a role in its development, but there's mixed evidence on how well IL-17A inhibitors work in treating it.
  • This study pooled data from various clinical trials comparing the effects of bimekizumab (a monoclonal antibody that targets both IL-17A and IL-17F) and a placebo on the incidence of uveitis.
  • Results showed that patients on bimekizumab had a significantly lower rate of uveitis compared to those receiving placebo, suggesting that bimekizumab may provide protective effects against uveitis in these patients.
View Article and Find Full Text PDF

Background: Patients with active axial spondyloarthritis (axSpA) exhibit more absences and lower levels of productivity in the workplace and household than the general population, which can improve upon treatment.

Objectives: The objective of this study is to determine the long-term impact of achieving different levels of clinical response or disease activity on workplace and household productivity in patients with axSpA.

Design: RAPID-axSpA (NCT01087762) was a 204-week phase III trial evaluating the safety and efficacy of certolizumab pegol (CZP) in adult patients with active axSpA.

View Article and Find Full Text PDF